Equillium, Inc. · NASDAQ:EQ
Equillium — Merger or Acquisition (February 2022)
23 slides from Equillium's merger presentation, Feb 16, 2022
Slide 1: Equillium Acquisition of Bioniz Therapeutics
Equillium Acquisition of Bioniz Therapeutics 16 February 2022 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains forward-looking statements about Equillium, Inc. (the “Company”). In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these
Slide 3: Equillium Acquisition of Bioniz Therapeutics
Equillium Acquisition of Bioniz Therapeutics Acquiring pipeline of first-in-class, multi-cytokine inhibitors & product discovery platform Clinical-stage assets targeting validated inflammatory disease drivers 19.3% equity stake (5,699,492 shares) $307.5 potential milestone payments $57.5M in develop
Slide 4: Bioniz Acquisition: Rationale
Combined company pipeline composed of valuable, diversified, first-in-class assets targeting immuno-inflammatory disorders Complementary biology and indications to current itolizumab programs Clinically validated approach with proof-of-concept data Substantially increases near and mid-term milestone
Slide 5: Bioniz Acquisition: Rationale
Bioniz Acquisition: Rationale Deeper Pipeline Stronger Team Assets and personnel are complementary to itolizumab and EQ expertise Significant addition to near- and mid-term milestones Seamless, low-cost integration Continuity though retention of key experienced Bioniz employees as FTEs and/or adviso
Slide 6: Newly Expanded and Diversified Pipeline
Newly Expanded and Diversified Pipeline Drug Indication Delivery Pre-Clinical Phase 1 Phase 2 Phase 3 Status & Designations Itolizumab anti-CD6 acute graft-versus-host disease Pivotal study to support BLA filing FDA Fast Track and Orphan Drug Designations systemic lupus erythematosus (SLE) / lupus n
Slide 7: Acquired Assets & Opportunities
Acquired Assets & Opportunities
Slide 8: Proprietary Product Discovery Platform
Proprietary Product Discovery Platform Novel product Platform addresses the limitations of single-target biologics and broadly immunosuppressive therapies (e.g. JAKi) through peptide-based multi-cytokine inhibition Targeting validated biological and disease pathways Leveraging in-house expertise in
Slide 9: Targeted Inhibition of Disease-associated Cytokines
Targeted Inhibition of Disease-associated Cytokines
Slide 10: Optimized Modality Compared to mAbs and JAK Inhibitors
Optimized Modality Compared to mAbs and JAK Inhibitors Multi-cytokine inhibition without the safety liabilities of JAK inhibitors Insufficient Activity Safety Liabilities Improved Therapeutic Effect
Slide 11: BNZ-1 Development from Unique Structure-Based Discovery Platform
BNZ-1 Development from Unique Structure-Based Discovery Platform The gc receptor SAR BNZ-1 Structured-Domain Peptides IL-15 BNZ-1 IL-2 BNZ-1 IL-4 BNZ-1 The gc box
Slide 12: Bioniz: Differentiated Lead Assets & Broad Platform Potential
Bioniz: Differentiated Lead Assets & Broad Platform Potential CTCL Alopecia areata Vitiligo Rheumatoid arthritis Myositis Interstitial lung disease Administered by intravenous injection with subcutaneous delivery in development BNZ-1 IL-2 + IL-9 + IL-15 Celiac disease Inflammatory Bowel Disease SLE
Slide 13: BNZ-1: First-in-class Tri-Specific Cytokine Inhibitor
BNZ-1: First-in-class Tri-Specific Cytokine Inhibitor Inhibition of IL-2, IL-9, and IL-15 biology by BNZ-1 translates from preclinical models into humans 1) Nata et al., 2015; 2) Massoud et al, 2015 PNAS 3) Wang et al, 2018, 4 5) Tagaya et al., 2020 BNZ-1 inhibits IL-2/9/15, but not IL-4/7/211 IL-2
Slide 14: BNZ-1: Phase 1/2 Proof of Concept Study in CTCL
BNZ-1: Phase 1/2 Proof of Concept Study in CTCL Clinically validated with favorable safety profile, Phase 2/3 ready to address multiple indications with significant unmet medical need In cutaneous T cell lymphoma (CTCL), IL-2, IL-9, and IL-15 drive the cancer cell proliferation and increased inflamm
Slide 15: BNZ-1: Clinically Validated in Severe Dermatological Disease
CTCL disease stage IB/II Mogamulizumab (n=68) Vorinostat (n=72) BNZ-1 (n=19) Response Rate (mSWAT, CR + PR) 27.9% 19.4% 42.1%2 BNZ-1: Clinically Validated in Severe Dermatological Disease BNZ-1 reduces IL-2 & IL-15 dependent cells and inflammation with improvements in skin lesions and ORR comparing
Slide 16: BNZ-1: Clinical PoC Sets Up Indication Expansion
BNZ-1: Clinical PoC Sets Up Indication Expansion Prioritizing Phase 2 in alopecia areata with potential to target multiple follow-on indications with significant unmet medical need Proof-of–concept achieved in CTCL Demonstrated inhibition of IL-2 & IL-15 dependent inflammation with improvements in s
Slide 17: BNZ-2: First-in-class Dual Cytokine Inhibitor Targeting GI Inflammation
IL-15 and IL-21 work together driving GI inflammation in celiac disease and inflammatory bowel disease patients1,2 BNZ-2 inhibits important biology in multiple preclinical models BNZ-2 inhibits the IL-15 and IL-21 induced signaling pathways in celiac patient-derived intraepithelial cytotoxic T-Lymph
Slide 18: BNZ-2: Dual Action Provides Advantage in Treating Celiac Disease
BNZ-2: Dual Action Provides Advantage in Treating Celiac Disease Healthy gut epithelium + Gluten BNZ-2 IL-21 Autoantibodies Celiac disease Epithelial cell death and villous atrophy Autoreactive CD8+ IE- CTLs BNZ-2 IL-15/IL-21 Gluten-specific CD4+ cells Elevated levels of IL-15 & IL-21 synergisticall
Slide 19: BNZ-2: Poised for Clinical Advancement
Potential to be a differentiated asset in the GI space addressing key inflammatory drivers IL-15 and IL-21 Lead indication: celiac disease Attractive commercial opportunity with favorable competitive environment BNZ-2 potentially addresses unmet need for refractory patients Phase 1 SAD/MAD planned w
Slide 20: Creating Value through Novel Product Discovery Platform
Flexible, structure-based peptide discovery technology enables development of a range of therapeutic agents including: Additional gc-targeted cytokine inhibitors 2nd generation products such as Fc-fusion molecules Receptor agonists to activate pathways for use in oncology Orally administered, locall
Slide 21: Combined Catalysts & Milestones
Combined Catalysts & Milestones Growing number of near and mid-term catalysts Additional data events to be announced as studies are initiated Catalysts & Milestones Expected Timing Itolizumab: Initiate Phase 3 pivotal study in first-line aGVHD Early 2022 Itolizumab: Interim data from Phase 1b EQUALI
Slide 22: Itolizumab remains a top priority
Itolizumab remains a top priority aGVHD pivotal study expected to initiate imminently Lupus nephritis Phase 1b interim data expected mid-2022 Acquisition of first-in-class complementary assets focused on high profile, clinically validated drug targets Significant value-driving near and mid-term mile
Slide 23: Thank you!
Thank you! Equillium, Inc. 2223 Avenida de la Playa / Suite 108 La Jolla, CA 92037 www.equilliumbio.com